Nexalin Technology (NXL) Long-Term Investments (2023 - 2024)
Nexalin Technology (NXL) posted quarterly Long-Term Investments of $864.0 for Q4 2024, down 99.1% year-over-year from $96000.0 in Q1 2024, and down 99.14% quarter-over-quarter from $100651.0 in Q3 2024.
Nexalin Technology (NXL) Long-Term Investments (2023 - 2024) Analysis & Trends
Nexalin Technology's Long-Term Investments history runs 2 years deep, the most recent figure standing at $864.0 for Q4 2024.
- In Q4 2024, Long-Term Investments fell 99.1% year-over-year to $864.0; the TTM figure through Dec 2024 stood at $864.0 (down 99.1% YoY), while the FY2024 annual figure was $864.0, down 99.1% from the prior year.
- Long-Term Investments for Q4 2024 stood at $864.0, down from $100651.0 in the prior quarter.
- The five-year high for Long-Term Investments was $101783.0 in Q1 2024, with the low at $864.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 1.11 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 2.25 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 244.10 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 175.52 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | Nexalin Technology | 7.04 Mn | 6.03 Mn | 8,897.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 864.00 |
| Sep 30, 2024 | 100,651.00 |
| Jun 30, 2024 | 100,492.00 |
| Mar 31, 2024 | 101,783.00 |
| Dec 31, 2023 | 96,000.00 |
| Sep 30, 2023 | 96,000.00 |